In a clear display of investor confidence, Anthem Biosciences has raised INR 1,016.02 crore from anchor investors ahead of its upcoming initial public offering (IPO), which opens for subscription on 14 July 2025. The company allotted 1,78,24,999 equity shares at the upper end of the price band — INR 570 per share — under the anchor investor portion.
Anthem Biosciences anchor book saw robust participation from a diversified mix of domestic mutual funds, global institutional investors, sovereign entities, and insurance firms, underlining the attractiveness of the offering. In total, 60 anchor investors were allocated shares, making up close to 30% of the total issue size of INR 3,395 crore, which is entirely an offer for sale.
Anthem Biosciences Anchor Book: Mutual Funds Dominate the List
A noteworthy 59.5% of the Anthem Biosciences anchor allocation went to 18 domestic mutual fund houses, a positive signal for retail and institutional investors alike.
Major participants from the mutual fund space included:
- HDFC Mutual Fund – Pharma & Healthcare, Tax Saver, Manufacturing, Business Cycle Fund
- ICICI Prudential – Pharma & Healthcare Diagnostics Fund
- Kotak Mahindra Mutual Fund – Multiple thematic funds like Healthcare, MNC, Manufacturing in India
- Axis Mutual Fund – Midcap, Smallcap, Large & Midcap Fund
- Nippon India – Pharma Fund
- Aditya Birla Sun Life – Equity Hybrid ‘95, Pharma & Healthcare, ELSS
🌐 Global and Sovereign Funds Also Participate
In addition to domestic names, the Anthem Biosciences anchor book drew participation from foreign institutional investors, global funds, and sovereign wealth funds:
- Abu Dhabi Investment Authority
- Government Pension Fund Global (Norway)
- Amundi Funds – New Silk Road
- PineBridge Global Funds – India Equity
- WhiteOak Capital
- Franklin India Mid Cap Fund
- Hereford Funds – 360 ONE
- Tocu Europe III S.à r.l.
These inclusions further validate Anthem’s global credibility as a contract development and manufacturing organization (CRDMO).
🏢 Insurance Firms, PE, and Others Join the Mix
A number of insurance players and PE-backed funds also showed interest Anthem Biosciences anchor investors round:
- Tata AIA Life Insurance
- Bajaj Allianz Life Insurance
- Bharti AXA Life Insurance
- Axis Max Life Insurance
- Kotak Mahindra Life Insurance
- Edelweiss Recently Listed IPO Fund
- 3PIM India Equity (IFSC) – managed by noted fund manager Prashant Jain
- 360 ONE Flexicap Fund
💡 Company Snapshot
Anthem Biosciences is a leading Indian CRDMO offering services across drug discovery, development, and commercial manufacturing. The company boasts capabilities in advanced modalities like ADCs, RNAi, peptides, lipids, and oligonucleotides, and currently manages 242 active projects, including 16 in late-stage development.
With over 8,000 projects delivered to 550+ clients across 44 countries, Anthem is one of India’s fastest-growing biosciences companies. Its FY25 revenue stood at INR 1,844.55 crore, with a net profit of INR 451.26 crore and a 24.46% profit margin.
💼 IPO Details
- IPO Dates: 14 – 16 July 2025
- Price Band: INR 540 – 570 (INR 50 discount for employees)
- Total Issue Size: INR 3,395 crore (Offer for Sale only)
- Retail Allocation: 35%
- Listing: NSE and BSE
- Anchor Portion: INR 1,016.02 crore
- Lot Size: 26 shares
📌 Lead Managers & Registrar
- Book Running Lead Managers:
JM Financial, Citigroup Global Markets, J.P. Morgan India, Nomura - Registrar:
KFin Technologies
Final Words
With a strong anchor book featuring quality institutions and over 60% allocation to domestic MFs, Anthem Biosciences IPO is off to a promising start. The company’s differentiated position in the global CRDMO space, coupled with strong financial performance and marquee client base, makes it a compelling proposition. All eyes now turn to the retail and institutional response as the subscription window opens soon.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.